Patients in the miglitol/metformin treatment groupshowed a mean decrease in HbA1c from baseline to theend of the treatment period, while those in the placebo/metformin group showed a mean increase (®gure 1). Atthe end of treatment, a signi®cant effect in favour ofmiglitol/metformin compared to placebo/metformincould be seen (miglitol/metformin adjusted mean atend of treatment, 8.26% 6 1.13%; placebo adjustedmean at end of treatment, 8.67% 6 1.13%; miglitoltreatment effect, ± 0.21 6 1.13%; placebo treatmenteffect, + 0.22 6 1.17%, p = 0.011). Thus at endpoint theplacebo-subtracted mean change from baseline in HbA1ccaused by miglitol was ±0.43%.